---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-143665"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2025-06-20T23:59:59+00:00"
generated_at: "2026-05-19T00:49:32.896280+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics enters $50M common stock purchase agreement with Lincoln Park Capital

## Summary
- Plus Therapeutics signed a purchase agreement with Lincoln Park Capital for up to $50 million of common stock over 36 months.
- Lincoln Park commits to buy up to 300,000 shares per regular purchase (up to 500,000 at higher prices) at 97% of market price.
- The company will pay a $500,000 initial commitment fee in cash or stock, plus $500,000 after reaching $25 million in sales.
- Proceeds will fund working capital and a $17.3 million make-whole repayment to March 2025 warrant holders.
- Issuance beyond 10,194,593 shares requires shareholder approval unless average sale price exceeds $0.3576.

## SEC filing metadata
- accession: 0001193125-25-143665
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2025-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312525143665/0001193125-25-143665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312525143665/d925162d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-143665
- JSON: https://secwatch.observer/filing/0001193125-25-143665.json
- Plain text: https://secwatch.observer/filing/0001193125-25-143665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.